IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Allergan, Inc. v Galderma Research & Development [2015] APO 87
Patent Application: 2010252935
Title:Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
Patent Applicant: Galderma Research & Development
Opponent: Allergan, Inc.
Delegate: Dr M-A. Fam
Decision Date: 15 December 2015
Hearing Date: 23 November 2015, in Canberra
Catchwords: PATENTS – section 59 – opposition to the grant of a patent – grounds of novelty, inventive step, manner of manufacture, utility, fair basis and clarity considered – novelty – citation does not disclose all the features of the claims – inventive step – evidence does not establish that it would be a matter of routine to prepare an injectable composition comprising three active ingredients – claims define a manner of manufacture – claimed invention is useful – claims are fairly based and clear – opposition fails
Representation: Patent applicant: Bernadette Hawkins of Cullens
Opponent: Christian Dimitriadis SC and Gavin Recchia of Davies Collison Cave
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2010252935
Title:Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
Patent Applicant: Galderma Research & Development
Date of Decision: 15 December 2015
DECISION
The opposition fails on all grounds. Subject to appeal, I direct the application proceed to grant. Costs according to Schedule 8 are awarded against Allergan, Inc.
REASONS FOR DECISION
Background
The present application was filed by Galderma Research & Development (Galderma) and Symatese on 28 May 2010. Symatese subsequently assigned its rights in the application to Galderma. The application claimed priority from US 61/213322 having a filing date of 29 May 2009. Following examination, the application was advertised accepted on 9 January 2014. Galderma subsequently filed section 104 amendments on 2 January 2015 and the amendments were advertised allowed on 28 May 2015.
A notice of opposition was filed by Allergan, Inc. (Allergan) on 9 April 2014. A hearing was held in Canberra on 23 November 2015. Galderma was represented by Bernadette Hawkins of Cullens. Allergan was represented by Christian Dimitriadis SC and Gavin Recchia of Davies Collison Cave.
It is noted that the request for examination in relation to the application was filed on 23 November 2011. Consequently, substantive amendments of the Patents Act 1990 brought about by the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 do not apply to the present application. This includes the amendment to subsection 60 (3A) that allows the Commissioner to refuse a patent application if satisfied on the balance of probabilities that a ground of opposition exists. It is further noted that any subsequent references to sections of the Patents Act relate to the Patents Act 1990 prior to amendment by the Raising the Bar Act. A similar qualification applies to references to the Patents Regulations 1991.
Grounds of opposition
The original statement of grounds and particulars was filed on 9 July 2014. A request to amend the statement was filed on 9 November 2015 and…
Keep reading for free
Create a free CaseChat account to read Allergan, Inc. v Galderma Research & Development and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2015] APO 87
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi